← Patent-cliff monitor small molecule XELJANZ TOFACITINIB CITRATE
Loss of exclusivity August 2028 FDA regulatory exclusivity expiry
Company Pfizer → See this company's full patent-cliff portfolio Drug detail Brand name XELJANZ Active ingredient TOFACITINIB CITRATE Strength EQ 1MG BASE/ML Dosage form SOLUTION Route ORAL Modality Small molecule FDA approval September 2020 Marketing status RX
Listed patents Patent Expires Type RE41783*PED June 2026 — RE41783 December 2025 substance
Regulatory exclusivity Code Expires PED August 2028 M-14 February 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.